Industry
From U.S. (Toll Free) : +16467917070    |   UK : +442030260021     |    sales@businessmarketinsights.com

Europe Travel Vaccines Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and Application (Domestic Travel and Outbound Travel)

Report Code :  BMIRE00025498
No. of Pages :  132
Published Month :  Jul 2022
Category :  Life Sciences
$299 per month

Best Plan
  • All Reports in One Industry
  • All Reports Read Access
  • Subscription Duration : 12 Months
  • Monthly New Reports Added
  • $1200 Yearly Saving

The travel vaccines market in Europe is expected to grow from US$ 995.47 million in 2021 to US$ 1,885.56 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028.

 

Hepatitis, HIV/AIDS, human papillomavirus (HPV), meningococcal disease, typhoid, and yellow fever are among the various chronic diseases detected across the region. Similarly, in 2021, the Centers for Disease Control and Prevention (CDC) launched the global immunization strategic framework 2021–2030. The framework provides a plan to vaccinate against vaccine-preventable diseases (VPDs), such as hepatitis A and B. Moreover, there are different vaccine routines for travelers proposed by WHO to prevent the spread of deadly infectious diseases. The vaccine routine includes routine vaccines for review before traveling, vaccines for certain destinations, and vaccines demanded by certain countries. In most cases, booster doses of routine vaccines are required if people have not followed the regular schedule. Such initiatives by WHO and CDC enhance the vaccine demand, thereby driving its market growth. On the other hand, the COVID–19 outbreak threatened public health. Various emergency actions were initiated during the pandemic, of which the COVAX initiative was aggressively enacted. Vaccination against COVID–19 was mandatory for people worldwide. Governments in every region mandated vaccines for people traveling within and outside countries. The COVID-19 pandemic contributed significantly to travel vaccines. Thus, the factors mentioned above are driving the market growth.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe travel vaccines market. The Europe travel vaccines market is expected to grow at a good CAGR during the forecast period.     

 

Europe Travel Vaccines Market Revenue and Forecast to 2028 (US$ Million)

 

Europe Travel Vaccines Market Segmentation         

 

Europe travel vaccines market is segmented into product, application, and country. The Europe travel vaccines market, by product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. The Europe travel vaccines market, by application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the Europe travel vaccines market is segmented into France, Germany, Italy, the UK, Russia, and the Rest of Europe.    

 

Abbott; Dynavax Technologies; Emergent BioSolutions Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and Valneva SE are among the leading companies in the travel vaccines market in the region.    

  1. Abbott
  2. Dynavax Technologies
  3. Emergent BioSolutions Inc.
  4. GlaxoSmithKline plc
  5. Merck & Co., Inc.
  6. Novartis AG
  7. Pfizer Inc.
  8. Sanofi
  9. Valneva SE.

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe travel vaccines market
  • Highlights key business priorities in order to assist companies to realign their business strategies 
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe travel vaccines market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the travel vaccines market, as well as those hindering it 
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution